Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Weibo Corp (WB) Price & Performance

Bristol-Myers Squibb CoTrade
Weibo CorpTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Weibo Corp — how do they compare? Bristol-Myers Squibb Co trades at $63.69 (market cap $129.94B), while Weibo Corp trades at $7.74 (market cap $1.93B). The key difference: Bristol-Myers Squibb Co is far larger — about 67.3× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (7.75%). Which is the better fit depends on your goals.

BMYWB
Market Cap
$129.94B$1.93B
Sector
HealthMedia
52-Week High
$65.89$12.83
52-Week Low
$42.60$7.20
Enterprise Value
$163.92B$1.20B
Dividend Yield
3.96%7.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.

BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.

Weibo Corp

Weibo (WB) trades at $7.98, up 0.5% with neutral technical signals. The stock shows compelling valuation metrics including a P/E of 5.5 and P/B of 0.5, trading below balance sheet value. Recent quarters show earnings misses but strong profitability with 21.15% net margin. Cash flow trends improved in 2025 with $408M net inflow, while revenue remains stable at $1.76B.

WB presents value opportunity with deep discount to fundamentals, though competitive pressures and recent earnings misses warrant caution. Analyst consensus leans bullish with 45% buy ratings, but structural challenges in user engagement and AI monetization create headwinds. The 8% dividend yield provides downside protection while investors await growth catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Weibo Corp

Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.

Read more on WB